Newsletter Signup | Join Community
Doctors demonstrate that adoptive immunotherapy can further improve chemotherapy treatment for early stage lung cancers.
IMPower133 clinical trial leads to Tecentriq Approval for initial treatment for SCLC: Imfinzi produces similar outcome
Selpercatinib is a precision cancer medicine that targets RET in some NSCLC patients.
Tepotinib is a novel precision cancer medicine capable of targeting NSCLC with MET 14 exon skipping alterations
Research suggests Metformin a widely used diabetic drug combined with a TKI may improve survival of EGFR mutated NSCLC.
The c-Met inhibitor Capmatinib is a promising novel precision cancer medicine for the treatment of EGFR + NSCLC.
Rova-T fails to improve outcomes in SCLC.
Early phase trial suggests PARP inhibitor combination show promise in treating hard to treat patients with SCLC
Study suggest immune checkpoint inhibitor therapy effective treatment for earlier stage NSCLC.
Imfinzi immunotherapy becomes standard treatment for stage III NSCLC - decreases progression and prolongs survival.
The BiTE antibody construct may represent the next advance in the treatment of EGFR + NSCLC.
Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC.
Avastin can be effectively combined with chemotherapy, immunotherapy, and tyrosine kinase inhibitors to treat NSCLC.
Patients With NSCLC Are Not Undergoing Biomarker Testing for Precision Medicines-Patient Education is Key
Research suggests that tumor mutational burden assessment can help predict response to immunotherapy in NSCLC.
BLU-667 targets RET fusion proteins and can be used to treat 1-2% of NSLC patients with the RET mutation.
Alcensa, Xalkori, and several other precision cancer medicines target ALK positive lung cancer and improve treatment.
The US Food and Drug Administration approves Keytruda for treatment of advanced SCLC.
Study suggests that first line chemotherapy + Iressa is a new standard treatment option for EGFR + NSCLC
Could Neoadjuvant Immunotherapy be The Next Major Treatment Advance for Early Stage Non-Small Cell Lung Cancer?
TAPUR study suggests CDKN2A + lung cancer can be targeted with breast cancer drug Ibrance
Lobrena - a third generation ALK inhibitor drug with excellent CNS activity
Gilotrif as a single agent or in combination improves survival in EGFR + NSCLC.
Treatment of multiple myeloma and cancers that spread to bone all benefit from XGEVA treatment.
Understand the role of PET/CT scanning in the management of Non-Small Cell Lung Cancer.
FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation.
PCI may improve survival in small cell lung cancer; new study suggests some benefit in early stage NSCLC.
The precision cancer medicine Tarceva targeting EGFR improves survival in stage I-III NSCLC & appears better than chemo!
Lung-MAP Precision Medicine Clinical Trial expanded to include all types of NSCLC including squamous and adenocarcinoma.
Stay Current With Lung Cancer Treatment Advances & Connect with Others
Genomic testing for "emerging biomarkers" like HER, MET and RET will become increasingly important for managing NSCLC.
Lung cancer is occurring more frequently in women: understand the causes and what can you do to lower your risk.
The WHO classifies air pollution as a carcinogen & ample evidence is emerging on it overall negative health consequences
Dana-Farber Cancer Institute’s Dr. Jackman M. D. discusses the latest advances in the management of lung cancer
Symptoms, Diagnosis and Treatment of Small Cell Lung Cancer
Immunotherapy with ALT-803 - checkpoint inhibitor combination may be next great advance in lung cancer treatment
Concerns about Tecentriq causes immune mediated kidney damage reported.
Precision cancer medicines advance the treatment of small cell lung cancer.
Lung Cancer Alliance
Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer
Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer
Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers
Gemzar® and Carboplatin Improve Survival in Advanced Non-Small Cell Lung Cancer
Dr. David Jackman of DFCI Discusses the Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer
Heavy Doses Of Vitamin B Supplements May Increase Lung Cancer Risk
Radiation Therapy can Enhance Effectiveness of Immunotherapy in People With Advanced Lung Cancer.
Anemia Prior to Chemotherapy Associated with Poorer Prognosis in Advanced Non-Small Cell Lung Cancer
Many Late Stage Lung Cancer Patients do not Receive Treatment.
Keytruda® Data Demonstrating Activity in Mesothelioma Presented at 17th World Conference on Lung Cancer.
Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues.
Advanced (NSCLC): Implications from Recent Trials
Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer.
Alecensa® Delays Cancer Progression Longer Than Xalkori® in Certain Lung Cancers.
MicroRNA Test Distinguishes Between Squamous and Non-Squamous Lung Cancer
Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows.
Ablation for Cancer Spread to the Chest Wall Relieves Pain and May Improve Survival
Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers
Aetna Provides Coverage for Biodesix’ VeriStrat Test
The new targeted agent Xilonix™ appears effective in the treatment a non–small cell lung cancer (NSCLC).
EGFR Testing in Advanced Lung Cancer Appears Underutilized
Sutent® Maintenance Therapy Found Active in Small-Cell Lung Cancer
NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer
Addition of Linifanib to Carboplatin-Paclitaxel Increases Free Survival
Cancer screening saves lives, but when it comes to lung cancer, early detection has long been a challenge.
Body Radiation Therapy Improves Survival in Stage IV Non Small Cell Lung Cancer
Advanced Squamous Cell Lung Cancer: The Lung-MAP Trial
Innovative Clinical Trials for Lung Cancer Currently Underway
Dacomitinib is an orally active, highly selective, second-generation small-molecule tyrosine kinase inhibitor.
Facing a lung cancer diagnosis?
Targeted - Individualized treatment for non–small cell lung cancer with precision cancer medicines is the new standard
1.Smoking causes the deadliest form of cancer.
Chest Radiation Improves Survival in Extended-Stage Small Cell Lung Cancer
Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival
CO-1686 Lung Cancer Treatment Receives Breakthrough Designation by FDA
Nintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC
Ganetespib Promising for Advanced Lung Cancer
Stereotactic Body Radiation Improves Lung Cancer Survival
Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer.
Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk
Air Pollution Causes Lung Cancer
Factors Affecting Quality of Life at the End of Life
Female Lung Cancer Deaths on the Rise in Some Areas
Diesel Exhaust Linked to Lung Cancer
PD-1 Targeted Immune Therapy Shows Promising Activity.
Diesel Exhaust Linked with Lung Cancer Deaths.
Drugs That Normalize Gene Expression Show Promise in Lung Cancer.
Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer
Extended Analysis Confirms That Chemotherapy in Early Non–Small Cell Lung Cancer Provides Survival Advantage
Complete Removal of Mediastinal Lymph Nodes Does Not Increase Complications in Early Lung Cancer
Benefit from Surgery in Stage IIIA N2 (NSCLC) in Medically Fit Patients
An Update from the Chemotherapy Foundation on Non-Small Cell Lung Cancer
Early Detection for Lung Cancer in Blood Test
Organ Transplant Recipients Have Increased Cancer Risk.
FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer
Higher Radiation Dose Does Not Benefit Lung Cancer Patients.
Elderly, Minorities and Women Under-represented in Lung Cancer Clinical Trials.
Genetic Assay Predicts Survival in Early Non-small Cell Lung Cancer.
Elderly Lung Cancer Patients May Benefit from Combination Chemotherapy.
Large Study Confirms that Vandetanib Is Active in Previously Treated Non–Small Cell Lung Cancer
Lung CT Scans Produce Variable Results.
Extending Alimta Treatment Delays Lung Cancer Progression.
Still No Evidence That Preventive Radiation to Brain Improves Survival with Non-Small Cell Lung Cancer.
Anti-estrogens May Reduce Risk of Lung Cancer Death
The anti-estrogen breast cancer medication tamoxifen appears to reduce the risk of death from lung cancer.
Fitness in Middle Age Reduces Cancer Risk in Men
Variety of Veggies and Fruits May Help Prevent Lung Cancer
Palliative care is care that is focused on symptom management, psychosocial issues, decision-making, and quality of life
Estrogen Alone Does Not Increase Lung Cancer Incidence or Mortality in Postmenopausal Women
Vitamin B6 Associated with Lower Risk of Lung Cancer
Some Blood Pressure Drugs May Raise Cancer Risk
Selenium Does Not Prevent Second Lung Cancers in Patients with Early Non-small Cell Lung Cancer
Lung Cancer Risk and Traffic-related Air Pollution
Concurrent Radiochemotherapy Improves Survival in NSCLC
Gene Signature Helps Predict Survival of Patients with Lung Cancer
Combined Hormone Replacement Therapy May Increase Women’s Risk of Lung Cancer
Adjuvant Chemotherapy Improves Non–Small Cell Lung Cancer Survival
Combination of Approaches Improves Detection of Lung Cancer in Bronchoscopy Specimens
Sterotactic Radiosurgery Alone Is Preferred Treatment for Newly Diagnosed Brain Metastases
Addition of Thalidomide to Chemotherapy Improves Survival in Small Cell Lung Cancer
Hormone Replacement Therapy in Postmenopausal Women May Increase the Risk of Dying from Lung Cancer
Iressa® and Taxotere® Provide Same Survival in Recurrent Non–Small Cell Lung Cancer
Evaluation of a Promising Cancer Vaccine Research Study in Early Stage Lung Cancer
Schizophrenia Associated with Increased Cancer Mortality
Alimta® Approved as Lung Cancer Maintenance Therapy
Additional Evidence of Abraxane™ Activity in Advanced Non-small Cell Lung Cancer
Erbitux® plus Improves Survival in Advanced Non–Small Cell Lung Cancer
First-line Iressa® Benefits EGFR-positive Patients with Advanced NSCLC Who Have Poor Performance Status
Gene May Suppress Lung Cancer Growth and Improve Survival
Disease Stabilization More Accurate than Responses in Predict Lung Cancer Outcomes
NSAIDs May Decrease Risk of Lung Cancer
Beta-carotene, Retinol, and Lutein Supplements May Increase Risk of Lung Cancer
Long-Term Exposure to Air Pollution May Increase Risk of Lung Cancer and Cardiopulmonary Disease
Combined Chemotherapy and Radiation Shows Promise for Patients with Non-Small Cell Lung Cancer
Combination of Markers Shows Promise in Detecting Lymph Node Metastasis in Non-Small Cell Lung Cancer
Combination Chemotherapy as Second-Line Therapy May Not Improve Outcomes for Patients with Non-Small Cell Lung Cancer
Chemotherapy Improves Survival in Older Patients with NSCLC Treated with Chemotherapy
Radiation Therapy Preferable to Surgery for Stage IIIA Non-Small Cell Lung Cancer.
Specific Mutations Associated with Improved Survival with Iressa® in Non-Small Cell Lung Cancer